HALO - Halozyme Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

HALO is currently covered by 9 analysts with an average price target of $60.95. This is a potential upside of $6.7 (12.35%) from yesterday's end of day stock price of $54.25.

Halozyme Therapeutics's activity chart (see below) currently has 148 price targets and 152 ratings on display. The stock rating distribution of HALO is 79.69% BUY and 20.31% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 90.7% with an average time for these price targets to be met of 296.63 days.

Highest price target for HALO is $75, Lowest price target is $49, average price target is $61.22.

Most recent stock forecast was given by MITCHELL KAPOOR from HC WAINWRIGHT on 29-May-2025. First documented stock forecast 02-Aug-2012.

Currently out of the existing stock ratings of HALO, 51 are a BUY (79.69%), 13 are a HOLD (20.31%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$72

$15.93 (28.41%)

$72

8 days ago
(29-May-2025)

27/30 (90%)

$17.27 (31.55%)

183

Buy

$62

$5.93 (10.58%)

$64

23 days ago
(14-May-2025)

5/6 (83.33%)

$14.09 (29.41%)

328

Hold

$65

$8.93 (15.93%)

$57

30 days ago
(07-May-2025)

8/8 (100%)

$-5.14 (-7.33%)

240

Hold

$58

$1.93 (3.44%)

$57

1 months 16 days ago
(21-Apr-2025)

8/8 (100%)

$0.71 (1.24%)

93

Buy

$75

$18.93 (33.76%)

$60

3 months 17 days ago
(20-Feb-2025)

5/6 (83.33%)

$17.56 (30.57%)

264

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is HALO (Halozyme Therapeutics) average time for price targets to be met?

On average it took 296.63 days on average for the stock forecasts to be realized with a an average price target met ratio 90.7

Which analyst has the current highest performing score on HALO (Halozyme Therapeutics) with a proven track record?

VIKRAM PUROHIT

Which analyst has the most public recommendations on HALO (Halozyme Therapeutics)?

Vikram Purohit works at MORGAN STANLEY and has 5 price targets and 1 ratings on HALO

Which analyst is the currently most bullish on HALO (Halozyme Therapeutics)?

Robert Wasserman with highest potential upside - $18.93

Which analyst is the currently most reserved on HALO (Halozyme Therapeutics)?

Eun Yang with lowest potential downside - -$43.07

Halozyme Therapeutics in the News

Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy?

Momentum investing is all about the idea of following a stock’s recent trend, which can be in either direction. In the ‘long’ context, investors will essentially be “buying high, but hoping to sell even higher.” And for investors following this methodology, taking advantage of trends in a stock’s price is key; once a stock establishes...

Halozyme Therapeutics, Inc. (HALO): Among the Best Cancer Stocks to Invest in for Long-Term Gain

We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take a look at where Halozyme Therapeutics, Inc. (NASDAQ:HALO) stands against other best cancer stocks to invest in for long-term gain. Surging Cancer Cases and Costs Drive Growth in the Global Oncology...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?